Please login to the form below

Not currently logged in
Email:
Password:

AZ gets EMA approval for heart drug Brilique

The EMA has granted pre-market approval for AZ's Brilique for use in preventing blood clots in patients with acute coronary syndromes

The European Medicines Agency (EMA) has granted AstraZeneca (AZ) pre-market approval for Brilique (ticagrelor), also known as Brilinta outside Europe, for its use in preventing blood clots in patients with acute coronary syndromes. The US Food and Drug Administration (FDA) said last week that it needed three more months to review the drug for approval in the US.

EMA's Committee for Medicinal Products for Human Use (CHMP) stated that the drug would reduce the risks of heart attacks when used in combination with aspirin. It is now subject to final approval by the European Commission and could be in use in Europe and the UK by spring 2011.

AZ are releasing the anti-clotting drug in order to compete in a market dominated by Plavix (clopidogrel), sanofi-aventis and Bristol-Myers Squibb's blockbuster heart drug and the second best-selling drug globally.

Anders Ekblom, executive vice-president for AZ's global medicines development said, "Brilique will provide an important treatment option for physicians."

Experts anticipate that Brilique will become a market leader and financial forecasts estimate that sales of the new drug could reach $2.31bn by 2015.

27th September 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
GCI Health

GCI Health is an integrated communications agency designed for and inspired by the ever-changing face of healthcare. In London, we...

Latest intelligence

Women in science
The role of women in science and technology
Why the lack of female leaders in pharma and life sciences is a problem that still needs to be fixed...
Maria Dahl
China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances
China secures a place at the forefront of innovative medicine...
Virtual Research Grants Submission and Approval Program
Impetus Digital summarizes how a client established an independent grant review committee and a virtual grant submission and approval program, without having to travel and meet in person....

Infographics